Literature DB >> 22099424

Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers.

A Tagliaferri1, C Di Perna, C Santoro, P Schinco, R Santoro, G Rossetti, A Coppola, M Morfini, Massimo Franchini.   

Abstract

BACKGROUND: The increased life expectancy of the hemophilia population, primarily as a result of advances in factor replacement therapy, has enabled hemophiliacs to reach an older age. Consequently, age-related diseases, such as cardiovascular disorders and cancers, are being increasingly recognized in such patients. However, only few data are available on such co-morbidities, their management and impact on the primary bleeding disorders.
OBJECTIVES: With the aim of investigating several still unclear issues regarding cancers in hemophilia patients, we conducted, on behalf the Italian Association of Hemophilia Centers (AICE), a study on cancers among Italian hemophiliacs. PATIENTS: Data pertaining to 122 hemophiliacs with 127 cancers between 1980 and 2010 were retrospectively collected in 21 centers of the AICE which chose to participate.
RESULTS: Sixty-nine percent of cancers were recorded during the decade 2001–2010. Eighty-three percent of patients were infected with hepatitis C virus (HCV) and 22% of them were also co-infected with human immunodeficiency virus (HIV). Forty-three percent of cancers were HCV-related, whereas 9%were HIV related. Virus-related cancers were more frequent and non-virus-related cancers less frequent in patients with severe hemophilia than in those with mild/moderate forms (P = 0.0004). The non-virus-related standardized mortality ratio (SMR) was 0.3. Hemorrhagic complications occurred more frequently in patients undergoing chemotherapy (14%) or radiotherapy (19%).
CONCLUSIONS: The results of the present study confirm that cancers have become a new challenge for physicians working in hemophilia centers and underline the need for prospective trials to better assess the epidemiology and to optimize the management of hemophiliacs with cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22099424     DOI: 10.1111/j.1538-7836.2011.04566.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  9 in total

Review 1.  Haemophilia and cancer: a personal perspective.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 2.  Current and evolving features in the clinical management of haemophilia.

Authors:  Antonio Coppola; Massimo Morfini; Ernesto Cimino; Antonella Tufano; Anna M Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

3.  Current status of Italian Registries on inherited bleeding disorders.

Authors:  Hamisa Jane Hassan; Massimo Morfini; Domenica Taruscio; Francesca Abbonizio; Adele Giampaolo; Yllka Kodra; Emily Oliovecchio; Luciano Vittozzi
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  The Incidence Rates and Standardized Incidence Ratios of Cancer in Hemophilic HIV/AIDS Patients in Taiwan.

Authors:  Marcelo Chen; Ian Jen; Gerald B Sharp; Yi-Ming Arthur Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

Review 5.  Management of Hemophilia in Older Patients.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

Review 6.  Comorbidities of cardiovascular disease and cancer in hemophilia patients.

Authors:  Jiaan-Der Wang
Journal:  Thromb J       Date:  2016-10-04

7.  Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Authors:  Chatree Chai-Adisaksopha; Mark W Skinner; Randall Curtis; Neil Frick; Michael B Nichol; Declan Noone; Brian O'Mahony; David Page; Jeffrey Stonebraker; Lehana Thabane; Mark Crowther; Alfonso Iorio
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

8.  High number of CD56(bright) NK-cells and persistently low CD4+ T-cells in a hemophiliac HIV/HCV co-infected patient without opportunistic infections.

Authors:  Giulia Fregni; Anaenza Freire Maresca; Valérie Jalbert; Anne Caignard; Daniel Scott-Algara; Elisabeth Bordé Cramer; Elisabeth Rouveix; Marie C Béné; Claude Capron
Journal:  Virol J       Date:  2013-01-26       Impact factor: 4.099

9.  Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018.

Authors:  Shermarke Hassan; Rory C Monahan; Evelien P Mauser-Bunschoten; Lize F D van Vulpen; Jeroen Eikenboom; Erik A M Beckers; Louise Hooimeijer; Paula F Ypma; Laurens Nieuwenhuizen; Michiel Coppens; Saskia E M Schols; Frank W G Leebeek; Cees Smit; Mariëtte H Driessens; Saskia le Cessie; Erna C van Balen; Frits R Rosendaal; Johanna G van der Bom; Samantha C Gouw
Journal:  J Thromb Haemost       Date:  2020-12-18       Impact factor: 5.824

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.